This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n19http://localhost/temp/predkladatel/
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F10%3A00051807%21RIV12-MSM-14110___/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n3http://linked.opendata.cz/ontology/domain/vavai/
n13http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
n12http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F10%3A00051807%21RIV12-MSM-14110___
rdf:type
n3:Vysledek skos:Concept
dcterms:description
Somatostatin analogs (SSA) are the standard diagnostic and treatment tools in the clinical management of patients with neuroendocrine tumors (NETs) expressing somatostatin receptors (SSTRs). Although symptomatic and biochemical control is obtained with SSA in the majority of functional NETs, antineoplastic effects of SSA are partial and of limited duration. The aim of this study was to quantify expression levels of five SSTR subtypes (SSTR1-SSTR5) and correlate them with the clinical outcomes of patients with NETs who underwent SSA therapy. The expression levels were analyzed using real-time polymerase chain reaction in a series of 22 metastatic NETs with a median time of 10 months on the SSA therapy (range 2-82 months). The median duration of disease stabilization in patients who developed progression (n=14) was 9 months (range 3-92 months). The median survival period for all patients was 44 months (range 3-175 months). Somatostatin analogs (SSA) are the standard diagnostic and treatment tools in the clinical management of patients with neuroendocrine tumors (NETs) expressing somatostatin receptors (SSTRs). Although symptomatic and biochemical control is obtained with SSA in the majority of functional NETs, antineoplastic effects of SSA are partial and of limited duration. The aim of this study was to quantify expression levels of five SSTR subtypes (SSTR1-SSTR5) and correlate them with the clinical outcomes of patients with NETs who underwent SSA therapy. The expression levels were analyzed using real-time polymerase chain reaction in a series of 22 metastatic NETs with a median time of 10 months on the SSA therapy (range 2-82 months). The median duration of disease stabilization in patients who developed progression (n=14) was 9 months (range 3-92 months). The median survival period for all patients was 44 months (range 3-175 months).
dcterms:title
Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs
skos:prefLabel
Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs
skos:notation
RIV/00216224:14110/10:00051807!RIV12-MSM-14110___
n5:aktivita
n9:Z n9:I
n5:aktivity
I, Z(MZ0MOU2005)
n5:cisloPeriodika
2
n5:dodaniDat
n14:2012
n5:domaciTvurceVysledku
n6:6760074 n6:1863630 n6:2912589 n6:2486725 n6:9710760 n6:7947429 n6:9564845 n6:5974291
n5:druhVysledku
n16:J
n5:duvernostUdaju
n11:S
n5:entitaPredkladatele
n18:predkladatel
n5:idSjednocenehoVysledku
260304
n5:idVysledku
RIV/00216224:14110/10:00051807
n5:jazykVysledku
n15:eng
n5:klicovaSlova
carcinoid; neuroendocrine tumors; prognosis; response prediction; somatostatin analogs; somatostatin receptors
n5:klicoveSlovo
n10:response%20prediction n10:prognosis n10:somatostatin%20analogs n10:somatostatin%20receptors n10:neuroendocrine%20tumors n10:carcinoid
n5:kodStatuVydavatele
US - Spojené státy americké
n5:kontrolniKodProRIV
[D6AA655A3700]
n5:nazevZdroje
Cancer Biotherapy and Radiopharmaceuticals
n5:obor
n17:FD
n5:pocetDomacichTvurcuVysledku
8
n5:pocetTvurcuVysledku
8
n5:rokUplatneniVysledku
n14:2010
n5:svazekPeriodika
25
n5:tvurceVysledku
Bednaříková, Markéta Valík, Dalibor Slabý, Ondřej Fabian, Pavel Vytopilová, Simona Svoboda, Marek Vyzula, Rostislav Šachlová, Milana
n5:wos
000277155900014
n5:zamer
n13:MZ0MOU2005
s:issn
1084-9785
s:numberOfPages
7
n12:doi
10.1089/cbr.2009.0708
n19:organizacniJednotka
14110